Literature DB >> 2029014

Effects of acetylsalicylic acid on renal function in patients with chronic heart failure.

G A Riegger1, H W Kahles, D Elsner, E P Kromer, K Kochsiek.   

Abstract

PURPOSE: We conducted a double-blind, placebo-controlled trial to determine whether the administration of acetylsalicylic acid has adverse effects on renal function in patients with moderate chronic congestive heart failure with and without stimulation of the renin system. PATIENTS AND METHODS: Forty patients were randomly assigned to one of the following four groups: Group 1, low sodium diet and placebo; Group 2, low sodium diet and acetylsalicylic acid; Group 3, normal sodium diet and placebo; or Group 4, normal sodium diet and acetylsalicylic acid. Patients were studied over 8 days. After Day 5, patients in Groups 2 and 4 received acetylsalicylic acid (500 mg three times a day). The low sodium diet consisted of 13.6 mmol of sodium per day and the normal sodium diet consisted of 136 mmol of sodium per day.
RESULTS: The low sodium diet resulted in a highly significant increase in the plasma renin (2p = 0.0001), aldosterone (2p = 0.0006), and urinary prostaglandin E2 (2p = 0.01) concentrations and the renal potassium excretion (2p = 0.0009), whereas renal sodium excretion was significantly reduced (2p = 0.0001). Severe sodium depletion led to a reduction of the glomerular filtration rate (2p = 0.007), which was independent from cyclooxygenase inhibition. In patients on the low sodium diet, acetylsalicylic acid reduced the elevated urinary prostaglandin E2 levels to normal values without changing the renal sodium excretion rate. In patients with a normal sodium intake, acetylsalicylic acid significantly reduced the renal sodium excretion rate by 29% (2p = 0.04).
CONCLUSION: We conclude that severe sodium depletion has adverse effects on kidney function in patients with heart failure due to a reduction in the glomerular filtration rate. Administration of acetylsalicylic acid in doses that reduce the synthesis of renal prostaglandin E2 significantly reduces renal sodium excretion.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2029014

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  5 in total

Review 1.  Aspirin and ACE-inhibitors: for wedding or funeral?

Authors:  I M Barbash; S Gottlieb; U Goldbourt; S Behar; J Leor
Journal:  J Thromb Thrombolysis       Date:  2001-04       Impact factor: 2.300

2.  Aspirin Does Not Increase Heart Failure Events in Heart Failure Patients: From the WARCEF Trial.

Authors:  John R Teerlink; Min Qian; Natalie A Bello; Ronald S Freudenberger; Bruce Levin; Marco R Di Tullio; Susan Graham; Douglas L Mann; Ralph L Sacco; J P Mohr; Gregory Y H Lip; Arthur J Labovitz; Seitetz C Lee; Piotr Ponikowski; Dirk J Lok; Stefan D Anker; John L P Thompson; Shunichi Homma
Journal:  JACC Heart Fail       Date:  2017-08       Impact factor: 12.035

Review 3.  Is aspirin safe for patients with heart failure?

Authors:  J G Cleland; C J Bulpitt; R H Falk; I N Findlay; C M Oakley; G Murray; P A Poole-Wilson; C R Prentice; G C Sutton
Journal:  Br Heart J       Date:  1995-09

Review 4.  Interaction between aspirin and ACE inhibitors in patients with heart failure.

Authors:  I Mahé; C Meune; M Diemer; C Caulin; J F Bergmann
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

5.  Effect of the Renin-Angiotensin-Aldosterone System Reactivity on Endothelial Function and Modulative Role of Valsartan in Male Subjects with Essential Hypertension.

Authors:  Jakub Jasiczek; Małgorzata Trocha; Arkadiusz Derkacz; Ewa Szahidewicz-Krupska; Adrian Doroszko
Journal:  J Clin Med       Date:  2021-12-13       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.